Acetate-free biofiltration to remove fibroblast growth factor 23 in hemodialysis patients: a pilot study.
CONCLUSION: FGF23 underwent a significant reduction during AFB. Such removal was greater than that induced by conventional hemodialysis as reported in the literature (19%-decrease using modified cellulosic membranes). This difference may be attributed to the ability of AFB hemodiafiltration to efficiently remove middle molecules by convection. Whether a better clearance of FGF23 during hemodialysis may result in improved cardiovascular outcomes in the long term needs to be confirmed by randomized controlled trials.
PMID: 28401422 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - Category: Urology & Nephrology Authors: Cernaro V, Lucisano S, Canale V, Bruzzese A, Caccamo D, Costantino G, Buemi M, Santoro D Tags: J Nephrol Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Dialysis | Heart | Hemodiafiltration | Hemodialysis | Hormones | Renal Failure | Study | Urology & Nephrology